The Financial Conduct Authority has scrapped the 7-day waiting period for connected research during UK equity IPOs and simplified information-sharing rules, publishing the changes in policy statement PS26/16 on 5 August 2026 (FCA). The regulator announced the move the prior day, framing it as an effort to support UK listings (FCA).

The 7-day delay formed part of the FCA's "equal information sharing" framework, which restructured how syndicate research is distributed relative to unconnected analyst input during the IPO process. Under the now-rescinded rules, connected research — that is, research produced by analysts within the underwriting syndicate — was subject to a mandatory waiting period before publication. The FCA's own consultation paper, CP26/14, acknowledged that the delay and the broader equal information sharing regime had "added unnecessary market risk and costs" (FCA). That consultation opened on 27 April 2026 (Reuters).

PS26/16 finalises what CP26/14 proposed. The consultation sought views on removing the 7-day delay and easing the information-sharing constraints that govern how and when connected research reaches the market during an offering. The policy statement confirms the FCA's decision to proceed with those changes, removing a layer of process that issuers and syndicates argued created timing risk and friction without a commensurate investor-protection benefit.

The broader context here is a sustained regulatory push to make the UK listing regime more competitive. In July 2024, the FCA fast-tracked its largest overhaul of company listing rules in decades (Reuters). In January 2026, the regulator eased rules for companies raising capital, requiring a prospectus only when issuing shares equal to 75% of existing capital (Reuters). By October 2025, the FCA was already considering further changes to accelerate IPO listings, including phasing out the two-stage filing system (Reuters). The removal of the 7-day connected research delay now follows as the latest concrete step in that trajectory.

The FCA has, however, flagged a structural caveat. Easing listing rules alone will not be sufficient to draw companies to London (Reuters). That admission matters for market participants assessing the likely impact of PS26/16. The IPO pipeline is a function of valuation differentials, liquidity depth, investor appetite, and macro conditions, not solely regulatory architecture. A faster research-release timeline reduces syndicate execution risk and may modestly compress the IPO marketing window, but it does not resolve the fundamental question of whether issuers perceive London as offering competitive pricing relative to alternative venues.

For syndicate desks and capital markets teams, the practical implication is straightforward. Connected research can now be published without the artificial delay that previously separated it from unconnected analyst output. This eliminates a sequencing constraint that complicated roadshow logistics and created windows where syndicate analysts were effectively sidelined relative to independent coverage. Transaction counterparties will need to update their IPO execution playbooks and information barrier protocols to reflect the revised regime. Compliance teams should review PS26/16 in detail, as the policy statement supersedes the corresponding rules in the FCA Handbook that implemented the original equal information sharing requirements.

The regulatory question now is whether incremental adjustments like this one, layered on top of the 2024 listing reforms and the January 2026 capital-raising changes, compound into a materially more attractive IPO environment, or whether they represent marginal refinements to a regime whose competitiveness depends on factors the FCA itself acknowledges are beyond its remit.